AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Feb 25, 2025
32559_dirs_2025-02-24_4f0e7ef9-5a19-48e3-9dbb-e5ff807f60cb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-02-20
Reporting Person: Azelby Robert (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-20 | Stock Option (Right to Buy) | $4.13 | A | 90000.00 | Acquired | 2035-02-19 | Common Stock (90000.00) | Direct |
Footnotes
F1: 1/3rd of the shares subject to the option vest on the first anniversary measured from February 20, 2025 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date.